Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
18/11/2025 12:26
Nov 18 (Reuters) - Esperion Therapeutics Inc ESPR.O: ESPERION PARTNER HLS THERAPEUTICS ANNOUNCES APPROVAL OF NILEMDO® FOR THE REDUCTION OF LDL-CHOLESTEROL IN CANADIANS AT RISK OF CARDIOVASCULAR DISEASE ESPERION THERAPEUTICS INC -COMMERCIAL LAUNCH FOR NILEMDO IS EXPECTED IN Q2 2026 Source text: nGNX8QqcJZ Further company coverage: ESPR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease